ADVANCED ENZYME TECHNOLOGIES Financial Statement Analysis
|
||
|
The Revenues of ADVANCED ENZYME TECHNOLOGIES have increased by 15.39% YoY .
The Earnings Per Share (EPS) of ADVANCED ENZYME TECHNOLOGIES has increased by 26.14 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
ADVANCED ENZYME TECHNOLOGIES Last 5 Annual Financial Results
[BOM: 540025|NSE : ADVENZYMES]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹624 Cr | ₹541 Cr | ₹529 Cr | ₹502 Cr | ₹444 Cr |
| Expenses | ₹419 Cr | ₹383 Cr | ₹327 Cr | ₹269 Cr | ₹241 Cr |
| Operating Profit (Excl OI) | ₹205 Cr | ₹158 Cr | ₹203 Cr | ₹233 Cr | ₹203 Cr |
| Other Income | ₹37 Cr | ₹25 Cr | ₹6.42 Cr | ₹8.85 Cr | ₹5.88 Cr |
| Interest | ₹4.12 Cr | ₹3.48 Cr | ₹2.96 Cr | ₹2.57 Cr | ₹4.08 Cr |
| Depreciation | ₹35 Cr | ₹35 Cr | ₹35 Cr | ₹29 Cr | ₹26 Cr |
| Profit Before Tax | ₹188 Cr | ₹140 Cr | ₹171 Cr | ₹210 Cr | ₹179 Cr |
| Profit After Tax | ₹137 Cr | ₹104 Cr | ₹124 Cr | ₹151 Cr | ₹133 Cr |
| Consolidated Net Profit | ₹133 Cr | ₹106 Cr | ₹120 Cr | ₹146 Cr | ₹129 Cr |
| Earnings Per Share (Rs) | ₹11.92 | ₹9.45 | ₹10.70 | ₹13.06 | ₹11.58 |
| PAT Margin (%) | 21.92 | 19.18 | 23.34 | 29.88 | 29.96 |
| ROE(%) | 10.72 | 8.94 | 12.04 | 16.77 | 17.61 |
| ROCE(%) | 14.78 | 12.26 | 16.66 | 22.93 | 23.21 |
| Total Debt/Equity(x) | 0.02 | 0.01 | 0.01 | 0.02 | 0.03 |
Key Financials |
||
| Market Cap | : | ₹ 3,977.5 Cr |
| Revenue (TTM) | : | ₹ 619.4 Cr |
| Net Profit(TTM) | : | ₹ 140.7 Cr |
| EPS (TTM) | : | ₹ 12.6 |
| P/E (TTM) | : | 28.3 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ADVANCED ENZYME TECHNOLOGIES | -4.2% | -3.2% | -1.6% |
| SUN PHARMACEUTICAL INDUSTRIES | 1% | 0.7% | 47.3% |
| CIPLA | 0.3% | -1.8% | 19.6% |
| DR REDDYS LABORATORIES | 6% | 11.8% | 20.3% |
| ZYDUS LIFESCIENCES | -1.5% | -0.1% | 47% |
| DIVIS LABORATORIES | -1.1% | -5.8% | 61.7% |
| MANKIND PHARMA | 3.7% | 11.4% | 59.4% |
| TORRENT PHARMACEUTICALS | 0.6% | 4.1% | 59.5% |
| LUPIN | 3.3% | 2.9% | 75.9% |
ADVANCED ENZYME TECHNOLOGIES Revenues
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 15.39 % |
| 5 Yr CAGR | 8.88 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹624 Cr | 15.39 | |
| Mar2023 | ₹541 Cr | 2.13 | |
| Mar2022 | ₹529 Cr | 5.49 | |
| Mar2021 | ₹502 Cr | 13.03 | |
| Mar2020 | ₹444 Cr | - | |
ADVANCED ENZYME TECHNOLOGIES Operating Profit
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 30.38 % |
| 5 Yr CAGR | 0.27 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹205 Cr | 30.38 | |
| Mar2023 | ₹158 Cr | -22.25 | |
| Mar2022 | ₹203 Cr | -12.90 | |
| Mar2021 | ₹233 Cr | 14.49 | |
| Mar2020 | ₹203 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 12.98 % |
| 5 Yr CAGR | -7.91 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 32.91% | 12.98 | |
| Mar2023 | 29.13% | -23.88 | |
| Mar2022 | 38.27% | -17.41 | |
| Mar2021 | 46.34% | 1.29 | |
| Mar2020 | 45.75% | - | |
ADVANCED ENZYME TECHNOLOGIES Profit After Tax
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 26.19 % |
| 5 Yr CAGR | 0.77 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹133 Cr | 26.19 | |
| Mar2023 | ₹106 Cr | -11.66 | |
| Mar2022 | ₹120 Cr | -18.06 | |
| Mar2021 | ₹146 Cr | 12.87 | |
| Mar2020 | ₹129 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 14.29 % |
| 5 Yr CAGR | -7.51 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 21.92 % | 14.29 | |
| Mar2023 | 19.18 % | -17.82 | |
| Mar2022 | 23.34 % | -21.89 | |
| Mar2021 | 29.88 % | -0.27 | |
| Mar2020 | 29.96 % | - | |
ADVANCED ENZYME TECHNOLOGIES Earnings Per Share (EPS)
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 26.14 % |
| 5 Yr CAGR | 0.73 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹12 | 26.14 | |
| Mar2023 | ₹9.45 | -11.68 | |
| Mar2022 | ₹11 | -18.07 | |
| Mar2021 | ₹13 | 12.78 | |
| Mar2020 | ₹12 | - | |
ADVANCED ENZYME TECHNOLOGIES Return on Capital Employed (ROCE)
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 20.55 % |
| 5 Yr CAGR | -10.67 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 14.78% | 20.55 | |
| Mar2023 | 12.26% | -26.41 | |
| Mar2022 | 16.66% | -27.34 | |
| Mar2021 | 22.93% | -1.21 | |
| Mar2020 | 23.21% | - | |
ADVANCED ENZYME TECHNOLOGIES Share Price vs Sensex
| Current Share Price | : | ₹355.5 |
| Current MarketCap | : | ₹ 3,977.5 Cr |
| Updated EOD on | : | Dec 24,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ADVANCED ENZYME TECHNOLOGIES | -4.2% |
-3.2% |
-1.6% |
| SENSEX | -2.7% |
-0.8% |
9.9% |
ADVANCED ENZYME TECHNOLOGIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 0.3% | 2.6% | 43.7% |
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
| S&P BSE MIDSMALLCAP | -3.3% | 3.7% | 29.1% |
| S&P BSE SMALL CAP | -3.4% | 4.6% | 30% |
No NSE index found
You may also like the below Video Courses
FAQ about ADVANCED ENZYME TECHNOLOGIES Financials
How the annual revenues of ADVANCED ENZYME TECHNOLOGIES have changed ?
The Revenues of ADVANCED ENZYME TECHNOLOGIES have increased by 15.39% YoY .
How the Earnings per Share (EPS) of ADVANCED ENZYME TECHNOLOGIES have changed?
The Earnings Per Share (EPS) of ADVANCED ENZYME TECHNOLOGIES has increased by 26.14 % YoY .
Check out Intrinsic Value of Peers of ADVANCED ENZYME TECHNOLOGIES
Compare Stock Analytics of Peers of ADVANCED ENZYME TECHNOLOGIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
